Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Science and Technology
|
BioVectra received funding in year to support the expansion of existing technologies in biomanufacturing and mRNA/pDNA vaccine production totaling $22.8M. The total commitment of the funding awarded from the Strategic Innovation Fund (SIF) relating to this project spanning 2022-2024 was $46.5M, the residual amount is expected to be disbursed in fiscal year 2024. This funding agreement was in the form of grant and non-interest bearing repayable loan. BioVectra also sought and secured funding from provincial government in PEI to support capital investment, labor cost and other operational costs associated with the biomanufacturing and mRNA/pDNA production. Those funding agreements came in the form of non-repayable grants totaling $10M and tax incentives, of which $3.3M was received during 2023 fiscal year and the residual is expected over years 2024-2030.
|
Grant, Contribution or Other Financial Benefit
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
BioVectra received funding in year to support the expansion of existing technologies in biomanufacturing and mRNA/pDNA vaccine production totaling $22.8M. The total commitment of the funding awarded from the Strategic Innovation Fund (SIF) relating to this project spanning 2022-2024 was $46.5M, the residual amount is expected to be disbursed in fiscal year 2024. This funding agreement was in the form of grant and non-interest bearing repayable loan. BioVectra also sought and secured funding from provincial government in PEI to support capital investment, labor cost and other operational costs associated with the biomanufacturing and mRNA/pDNA production. Those funding agreements came in the form of non-repayable grants totaling $10M and tax incentives, of which $3.3M was received during 2023 fiscal year and the residual is expected over years 2024-2030.
|
Grant, Contribution or Other Financial Benefit
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
BioVectra received funding to allow the corporation to expand API and scaled biologics capacity in the Atlantic Canada region from Canada’s Strategic Innovation Fund (SIF) in the amount of $21.1M, all of which was collected during 2021 fiscal year. Subsequent to 2021, BioVectra applied and received approval in for funding to expand existing technologies in biomanufacturing and mRNA vaccine production totaling $39.8M from the Strategic Innovation Fund (SIF). Both SIF funding agreements are in the form of grants and repayable loan. BioVectra also sought funding from provincial governments in both Nova Scotia and PEI to support capital investment, labor cost and other operational costs associated with the biomanufacturing and mRNA production. Those funding agreements came in the form of non-repayable grant, tax incentives and repayable contribution. BioVectra was awarded and collected funding in full in the amount of $1.87M from NRC-IRAP to develop a concept for the manufacturing of COVID-19 vaccines
|
Grant, Contribution or Other Financial Benefit
|
Communication techniques that have been used or are expected to be used in the course of the undertaking: